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ABSTRACT Translocation of effector proteins via a type III secretion system (T3SS) is a widespread infection strategy among
Gram-negative bacterial pathogens. Each pathogen translocates a particular set of effectors that subvert cell signaling in a way
that suits its particular infection cycle. However, as effector unbalance might lead to cytotoxicity, the pathogens must employ
mechanisms that regulate the intracellular effector concentration. We present evidence that the effector EspZ controls T3SS ef-
fector translocation from enteropathogenic (EPEC) and enterohemorrhagic (EHEC) Escherichia coli. Consistently, an EPEC
espZ mutant is highly cytotoxic. Following ectopic expression, we found that EspZ inhibited the formation of actin pedestals as it
blocked the translocation of Tir, as well as other effectors, including Map and EspF. Moreover, during infection EspZ inhibited
effector translocation following superinfection. Importantly, while EspZ of EHEC O157:H7 had a universal “translocation stop”
activity, EspZ of EPEC inhibited effector translocation from typical EPEC strains but not from EHEC O157:H7 or its progenitor,
atypical EPEC O55:H7. We found that the N and C termini of EspZ, which contains two transmembrane domains, face the cyto-
solic leaflet of the plasma membrane at the site of bacterial attachment, while the extracellular loop of EspZ is responsible for its
strain-specific activity. These results show that EPEC and EHEC acquired a sophisticated mechanism to regulate the effector
translocation.
IMPORTANCE Enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC) are important diarrheal patho-
gens responsible for significant morbidity and mortality in developing countries and the developed world, respectively. The viru-
lence strategy of EPEC and EHEC revolves around a conserved type III secretion system (T3SS), which translocates bacterial pro-
teins known as effectors directly into host cells. Previous studies have shown that when cells are infected in two waves with
EPEC, the first wave inhibits effector translocation by the second wave in a T3SS-dependent manner, although the factor in-
volved was not known. Importantly, we identified EspZ as the effector responsible for blocking protein translocation following a
secondary EPEC infection. Interestingly, we found that while EspZ of EHEC can block protein translocation from both EPEC
and EHEC strains, EPEC EspZ cannot block translocation from EHEC. These studies show that EPEC and EHEC employ a novel
infection strategy to regulate T3SS translocation.
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Type III secretion systems (T3SS) are nanosyringes used by alarge number of Gram-negative pathogenic bacteria of hu-
man, animals and plants (e.g., Salmonella, Shigella, Yersinia, Pseu-
domonas, Xanthomonas, Chlamydia, enteropathogenic Esche-
richia coli, and enterohemorrhagic E. coli) to translocate effector
proteins directly from the bacterial cytosol into eukaryotic cells
(reviewed in reference 1). The T3SS is embedded in the bacterial
cell wall and consists of many different proteins and hundreds of
individual subunits. The secretion apparatus is comprised of a
basal body (consisting of stacked rings joined by a central rod) and
an external “needle” (2). At the other end of the T3SS are compo-
nents of the translocon, which directly interact with the eukaryotic
membrane to form a translocation pore and a contiguous secre-
tion channel between the bacterial and eukaryotic cytosol (re-
viewed in reference 3). A cytoplasmic ATPase, related to the cata-
lytic subunits of bacterial FoF1 ATPases, energizes, via a proton
motive force, effector protein translocation. Following transloca-
tion, the effectors target different organelles and signaling path-
ways, which define the infection strategy of each pathogen (re-
viewed in reference 4).
The multifunctional nature of the effectors and the fact that
they can exhibit either synergistic or antagonistic activities sug-
gests that the timing of their translocation has to be tightly coor-
dinated. This is achieved at different levels, from the magnitude
and timing of gene expression in the bacterial cell (5) to a hierar-
chy of effector protein translocation (6). Indeed, real-time analy-
sis of effector translocation in enteropathogenic E. coli (EPEC)
revealed a distinct order of protein translocation (7). Moreover,
these studies showed that adherent EPEC can inhibit protein
translocation from a second wave of infecting bacteria in a T3SS-
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dependent manner (7), although the effector involved in this phe-
nomenon was not known.
EPEC and enterohemorrhagic E. coli (EHEC) are important
human pathogens. While EPEC strains cause bacterial pediatric
diarrhea and mortality in developing countries (8), EHEC strains,
particularly those belonging to serotype O157:H7, are associated
with food-born outbreaks in developed countries, causing ab-
dominal pain, nonbloody or bloody diarrhea, and, in about 10%
of patients, hemolytic uremic syndrome (HUS) (9). Although
they cause somewhat different diseases, EPEC and EHEC colonize
the gut mucosa via formation of attaching-and-effacing (A/E) le-
sions, which are characterized by intimate attachment of the bac-
teria to the apical membrane of enterocytes and effacement of the
brush border microvilli (10). In vitro, the hallmark of EPEC and
EHEC infection is formation of actin-rich pedestals (11). Forma-
tion of A/E lesions in vivo and actin pedestals in vitro is dependent
on the locus of enterocyte effacement (LEE) pathogenicity island
(12). The LEE encodes transcriptional regulators, the adhesin in-
timin (13), a T3SS (14-16), chaperones, and seven effectors (Tir,
Map, EspF, EspZ, EspH, EspB, and EspG) (reviewed in reference
17). Translocated Tir serves as an intimin receptor (18); intimin-
Tir interaction is essential for A/E lesion and pedestal formation
(19). Moreover, Tir (20) and EspH (21) downregulate filopodia
that are triggered at early stages of infection by the LEE-encoded
effector Map (20). At later stages of infection, Map traffics to the
mitochondria (22). Similarly, the LEE-encoded effector EspF also
targets the mitochondria, promoting mitochondrial dysfunction
and apoptosis (reviewed in reference 17). In addition, EPEC and
EHEC strains translocate multiple non-LEE-encoded effectors
with diverse activities, which are encoded by genes carried on
prophages and pathogenicity islands that are scattered around the
chromosome (17, 23). The LEE-encoded effector EspZ (24) is a
98-amino-acid effector consisting of an N-terminal translocation
signal (20 amino acids) (25) and two transmembrane domains
(TMDs) that target it to the plasma membrane of infected cells
(24). Importantly, an EPEC espZ mutant exhibits a high level of
cytotoxicity (4). The aim of this study was to investigate the cyto-
protection activity of EspZ.
RESULTS
An espZEPEC mutant is cytotoxic. To determine the role of EspZ
during infection, HeLa cells were infected for 3 h with the wild-
type EPEC strain E2348/69, E2348/69 espZ, and the comple-
mented mutant. Whereas only few cells infected with wild-type
E2348/69 or with the complemented espZ strain detached from
the monolayer, less than 30% of cells infected with E2348/69
espZ remained attached at the end of the incubation period (Fig.
1A and B). DNA staining, performed following 1 h of infection,
revealed that deletion of espZ resulted in nuclear condensation
(nucleus100m2) in 70% of cells. In contrast, nuclear conden-
sation was seen in only 10 to 20% of the uninfected control cells or
cells infected with wild-type E2348/69 or the complemented mu-
tant (Fig. 1C and D).
To establish if the plasma membrane integrity was compro-
mised during infection with the espZ mutant, cells were infected
with wild-type E2348/69, E2348/69espZ, and the complemented
mutant for 30 min, washed, and incubated with propidium iodide
(PI). Accumulation of PI in cells was then monitored by live-cell
imaging for 30 min. While no accumulation of PI was observed in
uninfected cells (see Fig. S1A) or in cells infected with wild-type
(data not shown) and complemented (see Fig. S1C) strains, the
number of cells with red nuclei increased when cells were infected
with E2348/69 espZ (see Fig. S1B), suggesting that the plasma
membrane was permeabilized.
We next investigated the level of lactate dehydrogenase (LDH)
release following 2 h of infection of HeLa cells with wild-type
E2348/69, E2348/69 espZ, or the complemented mutant. Infec-
tion with E2348/69 escN (defective in T3SS) was used as a con-
trol. Less than 10% of the total LDH was found in the supernatants
of uninfected cells and cells infected with the wild type, the escN
mutant, and the espZ complemented mutant. In contrast, more
than 40% of the total LDH was released from cells infected with
E2348/69espZ (Fig. 1E). This result suggests that the cytotoxicity
is dependent on effector translocation and is mitigated by EspZ,
confirming a previous report (4).
In order to determine whether the observed cell loss and LDH
release seen following infection with E2348/69 espZ were due to
caspase-dependent apoptosis, we conducted infections in the
presence of the global caspase inhibitor zVAD-FMK (carbo-
benzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone).
Cells pretreated with zVAD-FMK prior to infection with
E2348/69 espZ showed levels of cell detachment (see Fig. S2 in
the supplemental material) and LDH release (Fig. 1E) similar to
those of untreated cells infected with E2348/69 espZ, suggesting
that caspases are not involved in cytotoxicity. Taken together,
these data suggest that the espZ mutant induces type III cell death
(oncosis), characterized by nuclear condensation, rapid mem-
brane permeabilization (IP accumulation in the cells), and cellular
swelling (LDH release), independently of caspase activation.
Translocated EspZ is localized at the bacterial attachment
site. EspZ, which localizes at the EPEC attachment site during
infection of epithelial cells, is predicted to contain two TMDs (4,
24). In order to determine the localization and topology of EspZ,
we fused a Myc tag to the N terminus (Myc-EspZ) and a tandem
four-hemagglutinin (HA) tag epitope to the C terminus (EspZ-
HA4) and replaced the putative loop between the two TMDs with
an HA tag (EspZLoop/HA). In order to localize EspZ during infec-
tion, HeLa cells were infected with wild-type E2348/69, E2348/69
espZ, E2348/69 espZ expressing Myc-EspZ, E2348/69 espZ
expressing EspZ-HA4, or E2348/69espZ expressing EspZLoop/HA.
E2348/69escN expressing EspZ-HA4 was used as a negative con-
trol. Immunofluorescence revealed strong EspZLoop/HA staining
only inside the bacteria and cytotoxicity following infection with
espZ expressing EspZLoop/HA, suggesting that replacement of the
loop abolished EspZ translocation and therefore prohibited fur-
ther investigation. In contrast, both Myc-EspZ and EspZ-HA4
were translocated and seen at the bacterial attachment sites (see
Fig. S3A in the supplemental material), but only after permeabi-
lization (see Fig. S3B). Moreover, while E2348/69espZ induced a
large LDH release, the levels of LDH in the supernatants of cells
infected with E2348/69 espZ expressing Myc-EspZ or E2348/69
espZ expressing EspZ-HA4 were equivalent to those in unin-
fected cells and cells infected with wild-type E2348/69 (data not
shown), confirming that Myc-EspZ and EspZ-HA4 were func-
tional. No specific EspZ staining was seen in cells infected with
E2348/69escN expressing EspZ-HA4 (see Fig. S3B). These results
suggest that both the N and C termini of EspZ are cytosolic and
therefore that EspZ integrates into the plasma membrane in a
hairpin loop topology.
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FIG 1 EPEC espZ mutant is cytotoxic. HeLa cells were infected with wild-type E2348/69, E2348/69 espZ, and complemented E2348/69 espZ pespZ.
Uninfected cells were used as a control. Hematoxylin-and-eosin staining was used to visualize adherent cells 3 h postinfection (A), and Hoechst staining was used
to visualize nuclei 1 h postinfection (C). Enumeration of the remaining cells 3 h postinfection revealed extensive cell detachment in monolayers infected with
E2348/69espZ but not in the uninfected cells or cells infected with wild-type E2348/69 or E2348/69espZ complemented with espZ. Significant differences from
uninfected cells are indicated by asterisks (P  0.01) (B). While deletion of espZ induced nuclear condensation (white arrows), no difference was observed
between cells infected with E2348/69 or E2348/69 espZ complemented with espZ and uninfected cells (C). Using AxioVision software to enumerate cells with
a condensed nucleus (100m2) (D) revealed a significant increase when cells were infected with E2348/69espZ compared to uninfected cells or cells infected
with wild-type E2348/69 or E2348/69 espZ complemented with espZ. Significant differences from uninfected cells are indicated by asterisks (P 0.01). Cells
were untreated or treated with 50 M zVAD-FMK 30 min prior to infection with wild-type E2348/69, E2348/69 escN, E2348/69 espZ, and complemented
E2348/69espZ (E). LDH release increased when cells were infected with E2348/69espZ. Significant differences from uninfected cells are indicated by asterisks
(P 0.01) (see also Fig. S1 and S2 in the supplemental material).
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Ectopic expression of EspZ inhibits actin reorganization. To
determine if ectopic expression of EspZ could protect cells from
the cytotoxic effect induced by E2348/69 espZ, we generated a
eukaryotic expression vector (prK5-myc-espZ). As ectopically ex-
pressed EspZ was reported to be localized at the mitochondria
(26), we first localized EspZ after ectopic expression of Myc-EspZ
in HeLa cells (HeLa-EspZ). Immunofluorescence with anti-Myc
antibodies revealed that EspZ was partially found at the plasma
membrane (see Fig. S4A in the supplemental material). To con-
firm this result, plasma membranes of HeLa-EspZ cells were pu-
rified and analyzed by Western blotting (see Fig. S4B). This re-
vealed that while the negative controls GADPH (cytoplasm
marker) and cytochrome c (mitochondria) were undetectable,
EspZ was partially present in the plasma membrane fraction.
HeLa-EspZ cells or HeLa cells expressing Myc-tagged green
fluorescent protein (HeLa-GFP) were then infected for 1 h with
wild-type E2348/69, E2348/69 espZ, or the complemented mu-
tant. DNA staining revealed that ectopic expression of EspZ
blocked E2348/69 espZ from inducing nuclear condensation
(data not shown). This result suggests that ectopic expression of
espZ inhibits cytotoxicity. Unexpectedly, although actin staining
revealed the presence of microvillus-like processes (MLP) on
HeLa-EspZ cells in the vicinity of adherent wild-type E2348/69
(Fig. 2A) and E2348/69 escN (data not shown), confirming our
previous observation of a T3SS-independent actin remodeling
mechanism (27), formation of actin pedestals was evident in less
than 5% of the HeLa-EspZ cells infected with wild-type E2348/69,
compared with 80% of the infected HeLa-GFP cells (Fig. 2A and
FIG 2 Cells ectopically expressing espZ are resistant to EPEC-induced pedestal and filopodium formation. HeLa-GFP and HeLa-EspZ cells were infected with
wild-type E2348/69 (A) or E2348/69map overexpressing Map (B). Actin was stained with TRITC-phalloidin (red), the Myc-tagged EspZ with mouse anti-Myc
(green), and EPEC with rabbit anti-O127 (blue). Transfected cells with pedestals (C) or with microcolony-associated filopodia (D) were quantified by immu-
nofluorescence. One hundred cells were counted from three independent experiments. Results are means and SD. A large proportion of HeLa-GFP cells exhibited
either pedestals or microcolony-associated filopodia, whereas neither pedestals nor filopodia were observed in HeLa-EspZ cells. Significant differences are
indicated by asterisks (P 0.01). Images are representative of three replicated experiments.
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C). In order to determine if this effect of EspZ was specific to Tir,
HeLa-GFP and HeLa-EspZ cells were infected for 15 min with
E2348/69 overexpressing Map, which induces extensive filopo-
dium formation during the first 30 min of infection (28). Immu-
nostaining and quantification revealed that less than 10% of mi-
crocolonies attached to the HeLa-EspZ cells were associated with
filopodia. In contrast, filopodia were seen in almost 100% of the
microcolonies attached to the HeLa-GFP cells (Fig. 2B and D).
Importantly, we recently reported that ectopic expression of Map,
EspM2, and EspT did not interfere with effector translocation
(29), suggesting that the ability of EspZ to block translocation is
specific.
EspZ inhibits effector translocation. To test the hypothesis
that HeLa-EspZ cells are not permissive for translocation, we
tracked effector translocation microscopically following infection
with E2348/69 tir expressing HA-tagged Tir, E2348/69 map
expressing HA-tagged Map, or E2348/69espF expressing FLAG-
tagged EspF. Tir-HA staining outlined the attached bacteria in the
control HeLa cells, but no HA staining was visible in HeLa-EspZ
cells (Fig. 3A). Similarly, HA-tagged Map (see Fig. S5 in the sup-
plemental material) and FLAG-tagged EspF (Fig. 3B) were found
in the cytosol of HeLa but not HeLa-EspZ cells, suggesting that
EspZ inhibits translocation of Tir, Map, and EspF. We further
tested this hypothesis using the TEM1--lactamase translocation
assay (30). HeLa and HeLa-EspZ cells were infected with E2348/69
expressing EspF or Tir fused to TEM1. E2348/69 escN cells ex-
pressing EspF-TEM1 or Tir-TEM1 were used as negative controls.
Translocation of Tir (Fig. 3C) and EspF (Fig. 3D) was significantly
decreased in HeLa-EspZ cells compared to control HeLa cells.
Neither effector was translocated from E2348/69 escN. Notably,
some translocation of Tir but not EspF could be detected in EspZ-
transfected cells. This is likely due to the fact that not all the cells in
the monolayers are transfected and to the greater Tir translocation
efficiency. Taken together, these results suggest that EspZ inhibits
translocation of T3SS effectors.
Shames et al. (4) reported that EspZ may influence the PI3K/
Akt pathway. HeLa-GFP and HeLa-EspZ cells were treated for
30 min with the PI3K inhibitor LY-294002 and then infected with
wild-type E2348/69; pedestal formation was used as a marker for
protein translocation. No actin reorganization was seen in either
untreated or LY-294002-treated HeLa-EspZ cells (see Fig. S6 in
the supplemental material) compared to HeLa-GFP, suggesting
that the PI3K/Akt pathway was not involved in EspZ-mediated
inhibition of effector translocation.
EspZ blocks translocation from a second wave of EPEC infec-
tion. To determine if the cell toxicity observed with E2348/69
espZ was due to constitutive effector translocation, we used the
T3SS inhibitor protonophore CCCP (carbonyl cyanide
m-chlorophenylhydrazone), which has been shown to hinder
T3SS-mediated translocation fromYersinia enterocolitica (31) and
Shigella flexneri (32). We first determined if CCCP blocks the T3SS
of wild-type EPEC. Cells were infected with wild-type E2348/69
and treated either at the time of infection or 30 min later with
CCCP. Untreated cells were used as a control. While pedestals
were observed on untreated cells or cells treated with CCCP
30 min postinfection, MLPs in the absence of pedestals were ob-
served on cells that were coinoculated with EPEC and CCCP (Fig.
4A). These results suggest that CCCP can block EPEC T3SS while
not affecting cell signaling of already-translocated effectors. We
next quantified the levels of LDH release in the absence or pres-
ence of CCCP. Infected cells were treated with CCCP 30 or 60 min
following EPEC infection. Uninfected cells were used to control
the level of LDH release induced by the CCCP itself. E2348/69
espZ induced LDH release from the untreated cells or cells
treated with CCCP 60 min after EPEC inoculation (Fig. 3B). In
contrast, no LDH release was detected from cells treated with
CCCP 30 min after E2348/69 espZ inoculation. These results
suggest that arresting protein translocation at 30 min postinfec-
tion protected cells from toxicity, while at 60 min the level went
beyond the toxic threshold.
We recently showed that adherent EPEC bacteria block effec-
tor translocation from a second wave of EPEC infection in a T3SS-
dependent manner (7). This result suggests that an effector in-
jected by the first wave of EPEC infection is involved in arresting
translocation of effectors expressed by the second EPEC wave (7).
To determine if EspZ is involved in this phenotype, HeLa cells
were either left uninfected or infected for 30 min with wild-type
E2348/69, E2348/69 escV (T3SS mutant), or E2348/69 espZ.
The cells were then superinfected with E2348/69 expressing Tir
(Fig. 4C) or EspF (Fig. 4D) fused to TEM1, and the translocation
dynamic was monitored. A decrease in Tir and EspF translocation
was observed when the second wave of bacteria was used to infect
cells preinfected with wild-type E2348/69. In contrast, no inhibi-
tion was seen when cells were preinfected with E2348/69escV or
E2348/69espZ (Fig. 4C and D). These results further support the
hypothesis that EspZ blocks effector protein translocation.
Inhibition of protein translocation is serotype specific. We
next tested if EspZ from E2348/69 (EspZEPEC) can block effector
translocation from other EPEC and EHEC strains. HeLa-GFP and
HeLa-EspZEPEC cells were infected with EPEC serotypes O103:H2,
O111:H-, O55:H7, O55:H6, and EHEC O157:H7. Infection with
E2348/69 (O127:H6) was used as a control, and pedestal forma-
tion was used as a marker for protein translocation. The number
of infected cells with pedestals was quantified by epifluorescence
(Fig. 5A). All the EPEC and EHEC strains formed typical pedestals
upon infection of HeLa-GFP cells. In contrast, no pedestals were
observed in HeLa-EspZEPEC cells infected with E2348/69, EPEC
O103:H2, O111:H (Fig. 5B), or O55:H6. Importantly, EHEC
O157:H7 and EPEC O55:H7, the progenitor of EHEC O157 (33),
formed typical pedestals in the HeLa-EspZEPEC cells (Fig. 5C).
This result suggests that EspZEPEC is unable to block effector trans-
location from these strains. A similar approach was applied to test
the activity of EspZ from EHEC O157:H7 (EspZEHEC). Interest-
ingly, we found that EspZEHEC blocked the translocation from all
the EPEC and EHEC strains tested and thus has a wider inhibitory
range than EspZEPEC (Fig. 5A to C).
The translocon plays no role in the strain-specific activity of
EspZ. We previously reported that EspZ interacts with the pore-
forming translocon component EspD (34). In order to determine
if pore-forming proteins (EspD and EspB) or EspA (35) (which by
forming EspA filaments links the translocation pore with the nee-
dle complex) plays a role in the observed strain specificity of EspZ,
HeLa-GFP, HeLa-EspZEPEC, and HeLa-EspZEHEC cells were in-
fected with E2348/69 espB, E2348/69 espD, or E2348/69 espA
complemented with espB, espD, or espA from EPEC or from
EHEC. All the strains formed actin pedestals in GFP-HeLa cells
(data not shown), which confirmed that swapping the transloca-
tors between EPEC and EHEC did not interfere with the T3SS.
Moreover, neither strain formed pedestals in HeLa-EspZEPEC or
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FIG 3 Ectopic expression of espZ blocks effector translocation. HeLa or HeLa-EspZ cells were infected with E2348/69 tir expressing HA-tagged Tir (A),
E2348/69espF expressing Flag-tagged EspF (B), E2348/69 expressing Tir-TEM (C), or E2348/69 expressing EspF-TEM (D). E2348/69escN bacteria expressing
Tir-TEM or EspF-TEM fusions were used as negative controls. Myc-tagged EspZ was stained with mouse anti-Myc-FITC (green), HA-tagged and FLAG-tagged
effectors with mouse anti-HA and mouse anti-Flag, respectively (red), and EPEC with rabbit anti-O127 (blue). Tir and EspF were detected in the pedestal and
cytoplasm, respectively, in HeLa cells. In contrast, neither effector was detected in HeLa-EspZ cells. Images are representative of three replicated experiments.
Translocation assays using TEM fusions showed that Tir and EspF were translocated into HeLa cells. Significantly reduced translocation was seen in HeLa-EspZ
cells. No effector translocation was seen from the control strains. Results are the fold increase compared to uninfected cells from three independent experiments
and are presented as means and SD (*, P 0.01) (see also Fig. S5 in the supplemental material).
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FIG 4 EspZ blocks effector translocation from a second EPEC infection wave. Cells were infected with wild-type E2348/69 or E2348/69 espZ that was either
untreated or treated with CCCP (carbonyl cyanide m-chlorophenylhydrazone) at the time of infection or 30 or 60 min postinfection. For immunofluorescence
(A), actin was stained with TRITC-phalloidin (red) and EPEC with rabbit anti-O127 (green). LDH release (B) was measured after 2 h of infection. Treatment with
CCCP, which inhibits the T3SS of EPEC, 30 min postinfection did not block pedestal formation (white arrows) but inhibited LDH release induced by E2348/69
espZ. No inhibition of LDH release was observed in cells treated 60 min postinfection. Results are means and SD from three independent experiments (*, P
0.01). Cells were either left uninfected or infected with wild-type E2348/69, E2348/69escV, or E2348/69espZ and then superinfected with E2348/69 expressing
Tir-TEM (C) or EspF-TEM fusions (D). Translocation of effectors by the second wave of bacteria was monitored using a real-time translocation assay on
CCF2-preloaded cells. Translocation of Tir and EspF was reduced in cells preinfected with wild-type E2348/69. In contrast, similar translocation kinetics were
recorded in uninfected control cells or cells infected with E2348/69 escV or E2348/69 espZ, suggesting that EspZ can block effector translocation of a second
wave of infection. Results are means and SD from three independent experiments (*, P 0.01).
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HeLa-EspZEHEC cells. These results suggest that EspB, EspD, and
EspA are not involved in the strain-specific activity of EspZ.
In order to test if intimin, which is an outer membrane bacte-
rial protein, cooperates with EspZ (which is exposed on the
plasma membrane of infected cells) in determining host specific-
ity, HeLa-GFP, HeLa-EspZEPEC, and HeLa-EspZEHEC cells were
infected with E2348/69 eae complemented with eae (encoding
intimin) from either EPEC or EHEC. All the strains formed actin
pedestals in GFP-HeLa cells (data not shown), which confirmed
that swapping the intimin between EPEC and EHEC did not in-
terfere with the Tir signaling. Neither strain formed pedestals in
HeLa-EspZEPEC or HeLa-EspZEHEC cells. These results suggest
that intimin is not involved in the strain-specific activity of EspZ.
The extracellular loop of EspZ determines strain specificity.
EspZ consists of 98 amino acids, comprising an N-terminal trans-
location signal, two TMDs and a 10-amino-acid extracellular loop
(24). Alignment of EspZ orthologs showed that EspZ proteins
from EHEC O157:H7 and EPEC O55:H7 are identical (see Fig.
S7A in the supplemental material). However, little similarity was
seen between the sequences of the extracellular loops (amino acids
[aa] 65 to 74) of E2348/69 and EHEC O157:H7 (see Fig. S7A). In
order to determine if the extracellular loop plays a role in EspZ
specificity, we swapped the loops of EspZEPEC and EspZEHEC and
tested the ability of the ectopically expressed recombinant EspZ
variants to block translocation upon EPEC E2348/69 or EHEC
O157:H7 infection. HeLa-GFP, HeLa-EspZEPEC, and HeLa-
EspZEHEC cells were used as controls and pedestal formation as a
marker for protein translocation. The number of infected cells
with pedestals was determined by epifluorescence. All the recom-
binant EspZ variants were able to inhibit pedestal formation by
EPEC E2348/69 (see Fig. S7B). However, upon infection with
EHEC O157:H7, normal pedestals and Tir staining were observed
in cells expressing GFP, EspZEPEC, or EspZEHEC with the EPEC
loop (Fig. 6A). Importantly, inhibition of pedestal formation and
FIG 5 The activity of EspZ is serotype specific. HeLa-GFP, HeLa-EspZEPEC, or HeLa-EspZEHEC cells were infected with EPEC strains E2348/69 (O127:H6) and
B171 (O111:H) (B), EPEC strains ICC219 (O57:H6), E22 (O103:H2), and ICC57 (O55:H7) (C), and EHEC 85-170 (O157:H7). Actin was stained with
TRITC-phalloidin (red), Myc-tagged EspZ was detected with mouse anti-Myc (green), and DNA was detected with Hoechst (blue). Transfected cells with
pedestals were quantified by immunofluorescence (A). One hundred cells were counted from five independent experiments. Results are means and SD. Pedestals
were observed in HeLa-GFP and HeLa-EspZEPEC cells infected with ICC57 or 85-170 (B). No pedestals were observed in HeLa-EspZEHEC cells. Significant
differences from HeLa-GFP cells are indicated by asterisks (P 0.01).
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no Tir staining was detected in cells expressing EspZEHEC or Es-
pZEPEC with the EHEC loop (Fig. 6A and B). These results suggest
that the extracellular loop of EspZ plays an important role in the
strain-specific activity of EspZ.
In order to confirm that the loop swap does not alter the func-
tion of the proteins, HeLa cells were infected with wild-type
E2348/69, E2348/69 espZ, or E2348/69 espZ expressing EPEC
EspZ, EHEC EspZ, EPEC EspZ with the loop of EHEC, or EHEC
EspZ with loop of EPEC. Cells infected with E2348/69espZ com-
plemented with different mutants showed a level of LDH release
similar to that of cells infected with wild-type E2348/69 (see Fig.
S7C), confirming that the loop swap did not alter protein function
in EPEC. HeLa cells were then infected with wild-type EHEC
O157:H7 strain 85-170, 85-170espZ, and 85-170espZ express-
FIG 6 The extracellular loop of EspZ determines strain specificity. HeLa cells transfected with GFP, EspZEHEC, EspZEPEC, HeLa-EspZEHEC with the EPEC loop,
or EspZEPEC with the EHEC loop were infected with EHEC EDL933tir expressing HA-tagged Tir (A). Actin was stained with RRX-phalloidin (red), HA-tagged
Tir with mouse anti-Myc (green) and EPEC with rabbit anti-O157 (blue). Transfected cells with pedestals were quantified after immunofluorescence (B). One
hundred cells were counted from five independent experiments. EHEC formed pedestals associated with Tir staining in HeLa-GFP, HeLa-EspZEPEC or HeLa-
EspZEHEC with the loop of EPEC but not in HeLa-EspZEHEC or HeLa-EspZEPEC with the loop of EHEC. Results are presented as means  SD. Significant
differences from HeLa-GFP cells are indicated by asterisks (P 0.01). (c) LDH release was measured from cells infected for 3 h with wild-type 85-170, 85-170
espZ, or 85-170 espZ expressing EHEC EspZ, EPEC EspZ, EHEC EspZ with the EPEC loop, or EPEC EspZ with the EHEC loop. LDH release increased when
cells were infected with 85-170 espZ, 85-170 espZ expressing EPEC EspZ, or EHEC EspZ with the EPEC loop but not when cells were infected with 85-170
espZ expressing EHEC EspZ. Partial complementation was observed with 85-170espZ expressing EHEC EspZ and EPEC EspZ with the EHEC loop. Significant
differences from uninfected cells or from cells infected with 85-170 espZ are indicated (* and #, respectively; P  0.01) (see also Fig. S7 in the supplemental
material).
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ing EPEC EspZ, EHEC EspZ, EPEC EspZ with the loop of EHEC,
or EHEC EspZ with the loop of EPEC. As in EPEC, an EHEC
espZ mutant is highly toxic (exhibiting more than 70% of total
LDH release) compare to wild-type EHEC (10% of total LDH
release). Interestingly, whereas espZ from EHEC can complement
85-170 espZ, no complementation was observed with 85-170
espZ complemented with espZ from EPEC or with espZ from
EHEC with the loop of EPEC. In contrast, 85-170 espZ comple-
mented with espZ from EPEC with the loop of EHEC showed
partial complementation (Fig. 6C). Taken together, these results
confirmed that the loop of EspZ play a major role in recognizing
the infecting bacteria and inhibiting the T3SS.
DISCUSSION
T3SS effectors function in a coordinated manner. As effectors
from a single pathogen can complement or antagonize each other,
the timing and location of their activity, as well as their quantity,
must be highly regulated. It is therefore not surprising that bacte-
rial pathogens developed sophisticated mechanisms for spatial
and temporal control of effector protein activity. Timing of effec-
tor gene expression provides a basic regulatory level, while T3SS
chaperones assist in establishing an effector secretion hierarchy
within the bacterial cell (7, 36). In EPEC, translocation efficiency
is influenced by the effectors’ steady-state levels in the bacteria and
by two effector chaperones: CesF, which shows monospecificity
for EspF (37), and CesT, which participates in the translocation of
multiple effectors, including Tir, Map, EspH, and EspZ (38). The
effectors’ activity can also be regulated posttranslocation by mech-
anisms involving ubiquitination followed by proteasomal degra-
dation (e.g., SopE [39]), protein phosphorylation (e.g., Tir [18]),
or intracellular distribution via a specific hub (e.g., NleH, Map,
and EspI, which all bind the membrane scaffold protein NHERF2
[40]).
Another level of regulation, involving a negative feedback loop
on T3SS activity by an injected effector, was described for EPEC,
Yersinia, and Pseudomonas (1, 7, 41). The identity of the involved
EPEC effector remained elusive until now. In this study, we iden-
tified EspZ as the executor effector that mediates inhibition of
effector translocation. Upon infection, we confirmed that an
EPEC espZ mutant is highly toxic, probably due to a continuous
translocation and effector overload. Cells ectopically expressing
EspZ were refractory to effector protein translocation, as intracel-
lular Map, Tir, and EspF were undetectable. Moreover, inhibition
of T3SS by CCCP 30 min postinfection prevented cytotoxicity,
while addition of the compound 60 min postinfection was not
effective; suggesting that by 60 min the quantity of translocated
effectors passed the cytotoxic threshold. This is consistent with the
observation that the plasma membrane was permeabilized follow-
ing infection with the espZ mutant between 30 and 60 min postin-
fection.
A Citrobacter rodentium (the mouse pathogen equivalent to
EPEC [42]) espZ mutant is highly attenuated (6), suggesting that
the control of effector translocation is key to successful coloniza-
tion. Similarly, deletion of the Yersinia effector gene yopK (or
yopQ) caused attenuation in a mouse model (43) and led to in vitro
cytotoxicity (44). YopK/YopQ is a translocated cytosolic effector,
which although contains no TMDs binds the pore-forming trans-
locator YopB (45) and disrupts effector translocation (46). Inter-
estingly, we previously reported that EspZ interacts with the EPEC
pore-forming translocon component EspD (34). This interaction
might play a role in the EspZ antitranslocation activity, although
we have been unable thus far to coimmunoprecipitate EspZ and
EspD (our unpublished results), possibly due to the small amount
of EspD (as we were unable to detect EspD in cell lysates). More-
over, in Yersinia and Pseudomonas, the effectors YopE and ExoS
have been implicated in translocation control via their Rho-GAP
activity (1, 41). However, EspZ does not exhibit any similarity to
ExoS or YopE and is unlikely to be a Rho-GAP, or a Rho-GAP-
activation protein, since EspZ-expressing cells retain normal cy-
toskeletal organization. Based on the EspZ and YopK examples, it
is likely that mechanisms controlling effector injection have been
developed among bacteria employing T3SSs. However, in the ab-
sence of sequence or structural similarities between YopK and
EspZ, the identity of the functionally conserved effectors in other
bacteria is not easy to discover.
Recently, Shames et al. showed that EspZ interacts with the
membrane host cell protein CD98 (4). However, as the knock-
down of this protein did not alter the function of EspZ during
infection (4), CD98 does not appear to play a role in the modula-
tion of effector protein translocation. Uniquely, we found that the
extracellular loop of EspZ has a sensor-like activity, which medi-
ates strain specificity. While recombinant EspZ displaying the
loop of EPEC does not inhibit effector translocation from EHEC
O157:H7 and EPEC O55:H7, the loop of EHEC has a global activ-
ity, as it can inhibit protein translocation from all EPEC and
EHEC strains. How EspZ mediates its negative effect on the T3SS
activity is not clear yet, although a mechanism involving a specific
timing might be involved. Nevertheless, by analogy with the loop
of Tir that binds intimin on the bacterial outer membrane (26),
our results indicate that the exposed loop of EspZ might interact
with a secreted protein and/or with a bacterial outer membrane
protein.
Based on our data, we can now suggest a model (see Fig. S8 in
the supplemental material) in which, following infection, EspZ is
translocated and integrated in a hairpin loop topology into the
host cell plasma membrane. Then, by interacting with a strain-
specific, presumably exposed, protein, the extracellular loop of
EspZ transduces a signal (e.g., conformation change) to its N ter-
minus, which by interacting with EspD (a component of the trans-
location pore) arrests further effector translocation.
In summary, in this study we identified a novel T3SS EPEC/
EHEC effector that maintains the viability of infected cells by
gauging the duration of effector protein translocation via caspase-
and PI3K/Akt-independent mechanisms. This regulation is essen-
tial for successful colonization and infection. Understanding how
EspZ inhibits T3SS might lead to the development of new strate-
gies to control human and animal EPEC and EHEC infection and
carriage.
MATERIALS AND METHODS
Bacterial strains. TheE. coli strains used in this study are listed in Table S1
in the supplemental material. EPEC was cultured in LB broth at 37°C for
18 h with the appropriate antibiotics. Overnight cultures were diluted
1:100 in DMEM with low glucose (1,000 mg/liter) and grown for 3 h at
37°C without agitation. EHEC was directly cultured in DMEM with low
glucose and grown overnight at 37°C without agitation. Cells in 24-well
plates were infected with 25 l of overnight cultures. Isopropyl--d-
thiogalactopyranoside (1 mM) was added for 30 min when needed.
Molecular biology techniques. The plasmids and primers used in this
study are listed in Table S1 in the supplemental material. espZ was deleted
from EPEC strain E2348/69 and EHEC strain 85-170 using the lambda red
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system (47), generating strains ICC829 and ICC831, respectively. Primer
pairs F11/R11 (deletion for EPEC) and F11/R17 (deletion for EHEC) were
used to amplify the kanamycin cassette in pKD4. Primers F12/R12 and
F13/R13 were used to confirm the deletion in EPEC and F18/R18 was used
to confirm the deletion in EHEC. espZ was cloned into the bacterial ex-
pression vector pSA10 (48) following amplification from E2348/69 and
EDL933 genomic DNA using primer pair F1/R1 and primer pair F20/R20,
respectively. The PCR products were cloned into the EcoRI/SmaI sites of
pSA10, generating plasmids pICC1101 and pICC1111, respectively. The
espZ 4-HA tag was generated by inverse PCR using sequential PCRs from
pICC1101 with primers F2/R2, F3/R3, and F4/R4, generating plasmid
pICC1100. myc-tagged espZ was generated by inverse PCR from
pICC1101 with primer pair F19/R19, generating plasmid pICC1108. Mu-
tation of the loop with an HA tag was generated by inverse PCR from
pICC1101 with primer pair F20/R20, generating plasmid pICC1109. A
Tir-HA tag-expressing vector was obtained by amplification of tir from
EHEC TUV 93-0 genomic DNA as the template using primer pair F6/R6
and cloning into the SmaI/PstI sites of pSA10, generating plasmid
pICC1102. HA-tagged map was generated by inverse PCR using pSA10-
map (49) with primers F5 and R5, generating plasmid pICC1103. Pore
protein EspD was cloned into the bacterial expression vector pBAD/Myc-
His-C (Invitrogen) following amplification from E2348/69 and EDL933
genomic DNA using primer pairs F14/R14 and F15/R15. The PCR prod-
uct was cloned into the NcoI/EcoRI and NcoI/BglII sites of pBAD, gener-
ating plasmids pICC882 and pICC867. espB was cloned into the NcoI/
BglII sites of the bacterial expression vector pBAD following amplification
using primer pair F16/R16 and E2348/69 genomic DNA as the template,
generating plasmid pICC881. For cloning into a eukaryotic expression
vector, the espZ genes from EPEC and EHEC were amplified from
E2348/69 and EDL933 genomic DNA using primers F7/R7 and F8/R8,
respectively. The PCR products were cloned into the BamHI/EcoRI sites
of pRK5-myc, generating plasmids pICC1104 and pICC1105. The extra-
cellular espZ loops were exchanged by inverse PCR using primer pairs
F9/R9 and F10/R10 with pICC1101, pICC1104, pICC1105, and pICC1111
as the templates, generating plasmids pICC1112, pICC1106, pICC07, and
pICC1113.
Tissue culture and transfection. HeLa cells were grown at 37°C in a
5% CO2 atmosphere in DMEM supplemented with 10% (vol/vol) heat-
inactivated fetal calf serum (Invitrogen), nonessential amino acids
(Sigma), and 2 mM Glutamax (Invitrogen). Cells were transfected with
Fugene-6 (Roche) or GeneJuice (Merck) according to the manufacturer’s
recommendations. The global caspase inhibitor zVAD-FMK (Promega)
was used at a final concentration of 50 M. The protonophore carbonyl
cyanide m-chlorophenylhydrazone (CCCP; Sigma) was used at a final
concentration of 25 M.
Cell detachment assay. HeLa cells were seeded in 24-well plates. After
48 h, confluent cells were infected with primed bacteria for 1 h. Cells were
then washed five times with PBS every hour. After 3 h of infection, cells
were trypsinized and counted using a Malassez counting chamber. To
visualize cells after the infection, monolayers on coverslips were fixed with
paraformaldehyde (PFA) for 15 min, immersed in Harris hematoxylin
solution for 15 s, and subsequently washed with water until they appeared
blue. They were next treated with a 1% eosin solution for 5 s and briefly
rinsed with water. Coverslips were then mounted and observed with a
light microscope (Zeiss).
LDH release assay. HeLa cells were seeded in 24-well plates. After 48 h,
confluent cells were infected with primed bacteria for 1 h. Cells were then
washed five times with PBS and incubated with DMEM without dye for
one additional hour. Cell supernatants were then harvested, and the LDH
released was measured using a CytoTox 96 nonradioactive cytotoxicity assay
(Promega). The percentage of LDH released is calculated as the amount of
LDH measured in the supernatant divided by the total amount of LDH.
-Lactamase (TEM-1) translocation assay. HeLa cells were seeded in
96-well plates and transfected the following day. After 24 h, confluent cells
were infected with primed wild-type E2348/69 or E2348/69 escN bacte-
ria expressing either the Tir- or EspF-TEM1-fusion. The translocation
assay was performed as described previously (50).
Two-wave infection. The two-wave infection was conducted as de-
scribed by Mills et al. (7). Briefly, HeLa cells were seeded in 96-well plates
at a density of 3 104 cells/well. The following day, cells were incubated
with 1 M CCF2/AM (Invitrogen) and 2.5 mM probenecid for 1 h in the
dark at room temperature and then for 15 min at 37°C before being
infected for 30 min with the first wave of primed bacteria (Casamino
Acids-DMEM [CDMEM] supplemented with 2.5 mM probenecid). Fol-
lowing the first wave of infection, cells were washed gently with CDMEM
supplemented with probenecid and reinfected with the second wave of
bacterial cultures. Immediately upon infection, the plates were placed in a
plate reader (Spectrafluor Plus; Tecan) set at 37°C, and thus the infection
process took place in the plate reader. Cells were excited at 405 nm, and
emission at 465 nm and 535 nm was recorded at 150-s intervals.
Immunofluorescence microscopy. Cells were grown in 24-well cell
culture plates to 60 to 70% confluence. Monolayers were treated, infected,
and stained as described before (28). The coverslips were mounted in
ProLong Gold antifading agent (Invitrogen) and examined by conven-
tional epifluorescence microscopy using a Zeiss Axioimager microscope.
Deconvolution of the images was done with AxioVision LE re software
(Zeiss); the slice of interest was projected to form the new image.
Actin was detected with Oregon green phalloidin (Invitrogen) or
TRITC (tetramethyl rhodamine isocyanate) phalloidin (Sigma). Bacteria
were labeled with polyclonal anti-O127 and anti-O157 antibody (kindly
provided by Roberto La Ragione, Veterinary Laboratory Agency, United
Kingdom). Myc-tagged, HA-tagged, and FLAG-tagged proteins were la-
beled with monoclonal anti-Myc (Millipore), monoclonal anti-HA
(Cambridge Bioscience), or TRITC– conjugated monoclonal anti-HA
(Sigma) or monoclonal anti-FLAG (Sigma). AMCA-, Cy2-, RRX-, or
Cy5-conjugated donkey anti-mouse and anti-rabbit antibodies (Jackson
ImmunoResearch) were used as secondary antibodies. DNA was stained
using Hoechst (Sigma).
Statistical analysis. All experiments were conducted in triplicate and
repeated at least three times. Results were expressed as means standard
deviations (SD). The statistical significance was determined by two-way
analysis of variance (ANOVA) (GraphPad PRISM software), and aP value
of0.01 was considered significant.
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